{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:34:10Z","timestamp":1790051650418,"version":"4.0.1"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Transthyretin (TTR) is a tetrameric transport protein mainly synthesized by the liver and choroid plexus. ATTR amyloidosis is characterized by the misfolding of TTR monomers and their accumulation within tissues as amyloid fibres. Current therapeutic options rely on the blockade of TTR production, TTR stabilization to maintain the native structure of TTR, amyloid degradation, or induction of amyloid removal from tissues. \u201cAmyloid seeds\u201d are defined as small fibril fragments that induce amyloid precursors to assume a structure rich in \u03b2-sheets, thus promoting fibrillogenesis. Amyloid seeds are important to promote the amplification and spread of amyloid deposits. Further studies are needed to better understand the molecular structure of ATTR seeds (i.e. the characteristics of the most amyloidogenic species), and the conditions that promote the formation and multiplication of seeds in vivo. The pathological cascade may begin months to years before symptom onset, suggesting that seeds in tissues might potentially be used as biomarkers for the early disease stages. Inhibition of amyloid aggregation by anti-seeding peptides may represent a disease mechanism and treatment target in ATTR amyloidosis, with an additional benefit over current therapies.<\/jats:p>","DOI":"10.1007\/s10741-022-10237-7","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T18:07:16Z","timestamp":1649268436000},"page":"2187-2200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis"],"prefix":"10.1007","volume":"27","author":[{"given":"Paolo","family":"Morfino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-9519","authenticated-orcid":false,"given":"Alberto","family":"Aimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Panichella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Rapezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"10237_CR1","doi-asserted-by":"publisher","unstructured":"Griffin JM, Rosenblum H, Maurer MS (2021) Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res 128(10):1554\u20131575. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318187. PubMed PMID: 33983835","DOI":"10.1161\/CIRCRESAHA.121.318187"},{"key":"10237_CR2","doi-asserted-by":"publisher","unstructured":"Bezerra F, Saraiva MJ, Almeida MR (2020) Modulation of the Mechanisms driving transthyretin amyloidosis. Front Mol Neurosci 13:592644. https:\/\/doi.org\/10.3389\/fnmol.2020.592644. PubMed PMID:33362465; PubMed Central PMCID:PMCPMC7759661","DOI":"10.3389\/fnmol.2020.592644"},{"key":"10237_CR3","doi-asserted-by":"publisher","unstructured":"Emdin M, Aimo A, Rapezzi C et al (2019) Treatment of cardiac transthyretin amyloidosis: an update. Eur Heart J 40(45):3699\u20133706. https:\/\/doi.org\/10.1093\/eurheartj\/ehz298. PubMed PMID: 31111153","DOI":"10.1093\/eurheartj\/ehz298"},{"key":"10237_CR4","doi-asserted-by":"publisher","unstructured":"Saelices L, Nguyen BA, Chung K et al (2019) A pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils. J Biol Chem 294(15):6130\u20136141. https:\/\/doi.org\/10.1074\/jbc.RA118.005257. PubMed PMID:30733338;PubMed Central PMCID:PMCPMC6463714","DOI":"10.1074\/jbc.RA118.005257"},{"key":"10237_CR5","doi-asserted-by":"publisher","unstructured":"Saelices L, Chung K, Lee JH et al (2018) Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition. Proc Natl Acad Sci USA 115(29):E6741\u2013E6750. https:\/\/doi.org\/10.1073\/pnas.1805131115. PubMed PMID:29954863;PubMed Central PMCID:PMCPMC6055172","DOI":"10.1073\/pnas.1805131115"},{"key":"10237_CR6","doi-asserted-by":"publisher","unstructured":"Vieira M, Saraiva MJ (2014) Transthyretin: a multifaceted protein. Biomol Concepts 5(1):45\u201354. https:\/\/doi.org\/10.1515\/bmc-2013-0038. PubMed PMID: 25372741","DOI":"10.1515\/bmc-2013-0038"},{"key":"10237_CR7","doi-asserted-by":"publisher","unstructured":"Hamilton JA, Benson MD (2001) Transthyretin: a review from a structural perspective. Cell Mol Life Sci 58(10):1491\u20131521. https:\/\/doi.org\/10.1007\/PL00000791. PubMed PMID: 11693529","DOI":"10.1007\/PL00000791"},{"key":"10237_CR8","doi-asserted-by":"publisher","unstructured":"Wieczorek E, Ozyhar A. Transthyretin: from structural stability to osteoarticular and cardiovascular diseases. Cells. 2021 Jul 13;10(7). https:\/\/doi.org\/10.3390\/cells10071768. PubMed PMID: 34359938; PubMed Central PMCID: PMCPMC8307983","DOI":"10.3390\/cells10071768"},{"key":"10237_CR9","doi-asserted-by":"publisher","unstructured":"Blake CC, Geisow MJ, Oatley SJ et al (1978) Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J Mol Biol 121(3):339\u201356. https:\/\/doi.org\/10.1016\/0022-2836(78)90368-6. PubMed PMID: 671542","DOI":"10.1016\/0022-2836(78)90368-6"},{"key":"10237_CR10","doi-asserted-by":"publisher","unstructured":"Richardson SJ (2009) Evolutionary changes to transthyretin: evolution of transthyretin biosynthesis. FEBS J 276(19):5342\u20135356. https:\/\/doi.org\/10.1111\/j.1742-4658.2009.07244.x. PubMed PMID: 19725882","DOI":"10.1111\/j.1742-4658.2009.07244.x"},{"key":"10237_CR11","doi-asserted-by":"publisher","unstructured":"Aleshire SL, Bradley CA, Richardson LD et al (1983) Localization of human prealbumin in choroid plexus epithelium. J Histochem Cytochem 31(5):608\u2013612. https:\/\/doi.org\/10.1177\/31.5.6341455. PubMed PMID: 6341455","DOI":"10.1177\/31.5.6341455"},{"key":"10237_CR12","doi-asserted-by":"crossref","unstructured":"Raz A, Goodman DS (1969) The interaction of thyroxine with human plasma prealbumin and with the prealbumin-retinol-binding protein complex. J Biol Chem 244(12):3230\u20133237 PubMed PMID: 4978316","DOI":"10.1016\/S0021-9258(18)93118-2"},{"key":"10237_CR13","doi-asserted-by":"publisher","unstructured":"White JT, Kelly JW (2001) Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro. Proc Natl Acad Sci USA 98(23):13019\u201313024. https:\/\/doi.org\/10.1073\/pnas.241406698. PubMed PMID:11687657; PubMed Central PMCID:PMCPMC60817","DOI":"10.1073\/pnas.241406698"},{"key":"10237_CR14","doi-asserted-by":"publisher","unstructured":"Wieczorek E, Kedracka-Krok S, Bystranowska D et al (2021) Destabilisation of the structure of transthyretin is driven by Ca(2). Int J Biol Macromol 1(166):409\u2013423. https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.10.199. PubMed PMID: 33129902","DOI":"10.1016\/j.ijbiomac.2020.10.199"},{"key":"10237_CR15","doi-asserted-by":"crossref","unstructured":"Ciccone L Tonali, N, Shepard W, Nencetti S, Orlandini E (2021) Physiological metals can induce conformational changes in transthyretin structure: neuroprotection or misfolding induction? Crystals 11","DOI":"10.3390\/cryst11040354"},{"key":"10237_CR16","doi-asserted-by":"publisher","unstructured":"Zhao L, Buxbaum JN, Reixach N (2013) Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry 52(11):1913\u20131926. https:\/\/doi.org\/10.1021\/bi301313b. PubMed PMID:23414091; PubMed Central PMCID:PMCPMC3604100","DOI":"10.1021\/bi301313b"},{"key":"10237_CR17","doi-asserted-by":"publisher","unstructured":"Adam RD, Coriu D, Jercan A et al (2021) Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. ESC Heart Fail 8(4):2380\u20132396. https:\/\/doi.org\/10.1002\/ehf2.13443. PubMed PMID:34089308; PubMed Central PMCID:PMCPMC8318516","DOI":"10.1002\/ehf2.13443"},{"key":"10237_CR18","doi-asserted-by":"publisher","unstructured":"Ruberg FL, Grogan M, Hanna M et al (2019) Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 73(22):2872\u20132891. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003. PubMed PMID:31171094; PubMed Central PMCID:PMCPMC6724183","DOI":"10.1016\/j.jacc.2019.04.003"},{"key":"10237_CR19","doi-asserted-by":"publisher","unstructured":"Jacobson DR, Pastore RD, Yaghoubian R et al (1997) Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 336(7):466\u2013473. https:\/\/doi.org\/10.1056\/NEJM199702133360703. PubMed PMID: 9017939","DOI":"10.1056\/NEJM199702133360703"},{"key":"10237_CR20","doi-asserted-by":"publisher","unstructured":"Benson MD, Buxbaum JN, Eisenberg DS et al (2020) Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 27(4):217\u2013222. https:\/\/doi.org\/10.1080\/13506129.2020.1835263. PubMed PMID: 33100054","DOI":"10.1080\/13506129.2020.1835263"},{"key":"10237_CR21","doi-asserted-by":"publisher","unstructured":"Holmgren G, Costa PM, Andersson C et al (1994) Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet 31(5):351\u2013354. https:\/\/doi.org\/10.1136\/jmg.31.5.351. PubMed PMID:8064809; PubMed Central PMCID:PMCPMC1049863","DOI":"10.1136\/jmg.31.5.351"},{"key":"10237_CR22","doi-asserted-by":"publisher","unstructured":"Hellman U, Suhr O (2012) Regional differences and similarities of FAP in Sweden. Amyloid 19(Suppl 1):53\u201354. https:\/\/doi.org\/10.3109\/13506129.2012.670813. PubMed PMID: 22468675","DOI":"10.3109\/13506129.2012.670813"},{"key":"10237_CR23","doi-asserted-by":"publisher","unstructured":"Coelho T, Maurer MS, Suhr OB (2013) THAOS - The Transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 29(1):63\u201376. https:\/\/doi.org\/10.1185\/03007995.2012.754348. PubMed PMID: 23193944","DOI":"10.1185\/03007995.2012.754348"},{"key":"10237_CR24","doi-asserted-by":"publisher","unstructured":"Anselmi B, Conconi M, Veyrat-Durebex C et al (1998) Dietary self-selection can compensate an age-related decrease of rat liver 20 S proteasome activity observed with standard diet. J Gerontol A Biol Sci Med Sci 53(3):B173\u2013B179. https:\/\/doi.org\/10.1093\/gerona\/53a.3.b173. PubMed PMID: 9597040","DOI":"10.1093\/gerona\/53a.3.b173"},{"key":"10237_CR25","doi-asserted-by":"publisher","unstructured":"Keller JN, Hanni KB, Markesbery WR (2000) Impaired proteasome function in Alzheimer\u2019s disease. J Neurochem 75(1):436\u2013439. https:\/\/doi.org\/10.1046\/j.1471-4159.2000.0750436.x. PubMed PMID: 10854289","DOI":"10.1046\/j.1471-4159.2000.0750436.x"},{"key":"10237_CR26","doi-asserted-by":"publisher","unstructured":"Trigo D, Nadais A, da Cruz ESOAB. Unravelling protein aggregation as an ageing related process or a neuropathological response. Ageing Res Rev. 2019 May;51:67\u201377. https:\/\/doi.org\/10.1016\/j.arr.2019.02.001. PubMed PMID: 30763619","DOI":"10.1016\/j.arr.2019.02.001"},{"key":"10237_CR27","doi-asserted-by":"publisher","unstructured":"Swerdlow RH (2018) Mitochondria and mitochondrial cascades in Alzheimer\u2019s disease. J Alzheimers Dis 62(3):1403\u20131416. https:\/\/doi.org\/10.3233\/JAD-170585. PubMed PMID:29036828; PubMed Central PMCID:PMCPMC5869994","DOI":"10.3233\/JAD-170585"},{"key":"10237_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/B978-0-444-63486-3.00010-4","volume":"214","author":"M Morawski","year":"2014","unstructured":"Morawski M, Filippov M, Tzinia A, Tsilibary E, Vargova L (2014) ECM in brain aging and dementia. Prog Brain Res 214:207\u2013227","journal-title":"Prog Brain Res"},{"key":"10237_CR29","doi-asserted-by":"publisher","unstructured":"Longhi S, Guidalotti PL, Quarta CC et al (2014) Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovasc Imaging 7(5):531\u2013532. https:\/\/doi.org\/10.1016\/j.jcmg.2014.03.004. PubMed PMID: 24831216","DOI":"10.1016\/j.jcmg.2014.03.004"},{"key":"10237_CR30","doi-asserted-by":"publisher","unstructured":"Pinney JH, Whelan CJ, Petrie A et al (2013) Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc 2(2):e000098. https:\/\/doi.org\/10.1161\/JAHA.113.000098. PubMed PMID:23608605; PubMed Central PMCID:PMCPMC3647259","DOI":"10.1161\/JAHA.113.000098"},{"key":"10237_CR31","doi-asserted-by":"publisher","unstructured":"Obici L, Adams D (2020) Acquired and inherited amyloidosis: knowledge driving patients\u2019 care. J Peripher Nerv Syst 25(2):85\u2013101. https:\/\/doi.org\/10.1111\/jns.12381. PubMed PMID: 32378274","DOI":"10.1111\/jns.12381"},{"key":"10237_CR32","doi-asserted-by":"publisher","unstructured":"Reixach N, Deechongkit S, Jiang X et al (2004) Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA 101(9):2817\u20132822. https:\/\/doi.org\/10.1073\/pnas.0400062101. PubMed PMID:14981241; PubMed Central PMCID:PMCPMC365703","DOI":"10.1073\/pnas.0400062101"},{"key":"10237_CR33","doi-asserted-by":"publisher","unstructured":"Nochioka K, Quarta CC, Claggett B et al (2017) Left atrial structure and function in cardiac amyloidosis. Eur Heart J Cardiovasc Imaging 18(10):1128\u20131137. https:\/\/doi.org\/10.1093\/ehjci\/jex097. PubMed PMID: 28637305","DOI":"10.1093\/ehjci\/jex097"},{"key":"10237_CR34","doi-asserted-by":"publisher","unstructured":"Gillmore JD, Damy T, Fontana M et al (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39(30):2799\u20132806. https:\/\/doi.org\/10.1093\/eurheartj\/ehx589. PubMed PMID: 29048471","DOI":"10.1093\/eurheartj\/ehx589"},{"key":"10237_CR35","doi-asserted-by":"publisher","unstructured":"Ruberg FL, Maurer MS, Judge DP, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012 Aug;164(2):222\u2013228 e1. https:\/\/doi.org\/10.1016\/j.ahj.2012.04.015. PubMed PMID: 22877808","DOI":"10.1016\/j.ahj.2012.04.015"},{"key":"10237_CR36","doi-asserted-by":"publisher","unstructured":"Givens RC, Russo C, Green P et al (2013) Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center. Aging health 9(2):229\u2013235. https:\/\/doi.org\/10.2217\/ahe.13.10. PubMed PMID:24073013; PubMed Central PMCID:PMCPMC3780445","DOI":"10.2217\/ahe.13.10"},{"key":"10237_CR37","doi-asserted-by":"publisher","unstructured":"Grogan M, Scott CG, Kyle RA et al (2016) Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68(10):1014\u20131020. https:\/\/doi.org\/10.1016\/j.jacc.2016.06.033. PubMed PMID: 27585505","DOI":"10.1016\/j.jacc.2016.06.033"},{"key":"10237_CR38","unstructured":"Coutinho PM, Silva AMd, Lopes J et al (1980) editors. Forty years of experience with type I amyloid neuropathy. Review of 483 cases"},{"key":"10237_CR39","doi-asserted-by":"publisher","unstructured":"Mariani LL, Lozeron P, Th\u00e9audin M et al (2015) Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 78(6):901\u2013916. https:\/\/doi.org\/10.1002\/ana.24519. PubMed PMID:26369527;PubMed Central PMCID:PMCPMC4738459.eng","DOI":"10.1002\/ana.24519"},{"key":"10237_CR40","doi-asserted-by":"publisher","unstructured":"Koike H, Tanaka F, Hashimoto R et al (2012) Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry 83(2):152\u2013158.\u00a0https:\/\/doi.org\/10.1136\/jnnp-2011-301299. PubMedPMID:22228785;eng\u00a0","DOI":"10.1136\/jnnp-2011-301299"},{"key":"10237_CR41","doi-asserted-by":"publisher","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379(11):1007\u20131016. https:\/\/doi.org\/10.1056\/NEJMoa1805689. PubMed PMID: 30145929","DOI":"10.1056\/NEJMoa1805689"},{"key":"10237_CR42","doi-asserted-by":"publisher","unstructured":"Nativi-Nicolau J, Judge DP, Hoffman JE et al (2021) Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT. ESC Heart Fail 8(5):3875\u20133884. https:\/\/doi.org\/10.1002\/ehf2.13541. PubMed PMID:34432383;PubMed Central PMCID:PMCPMC8497209","DOI":"10.1002\/ehf2.13541"},{"key":"10237_CR43","doi-asserted-by":"publisher","unstructured":"Holmgren G, Steen L, Ekstedt J et al (1991) Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 40(3):242\u2013246. https:\/\/doi.org\/10.1111\/j.1399-0004.1991.tb03085.x. PubMed PMID: 1685359","DOI":"10.1111\/j.1399-0004.1991.tb03085.x"},{"key":"10237_CR44","doi-asserted-by":"publisher","unstructured":"Liepnieks JJ, Zhang LQ, Benson MD (2010) Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology 75(4):324\u2013327. https:\/\/doi.org\/10.1212\/WNL.0b013e3181ea15d4. PubMed PMID:20660862;PubMed Central PMCID:PMCPMC2918887","DOI":"10.1212\/WNL.0b013e3181ea15d4"},{"key":"10237_CR45","doi-asserted-by":"publisher","unstructured":"Buxbaum JN, Reixach N (2009) Transthyretin: the servant of many masters. Cell Mol Life Sci 66(19):3095\u20133101. https:\/\/doi.org\/10.1007\/s00018-009-0109-0 PubMed PMID:19644733;PubMed Central PMCID:PMCPMC4820353","DOI":"10.1007\/s00018-009-0109-0"},{"key":"10237_CR46","doi-asserted-by":"publisher","unstructured":"Carvalho A, Rocha A, Lobato L (2015) Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl 21(3):282\u2013292. https:\/\/doi.org\/10.1002\/lt.24058. PubMed PMID: 25482846","DOI":"10.1002\/lt.24058"},{"key":"10237_CR47","doi-asserted-by":"publisher","unstructured":"Yazaki M, Mitsuhashi S, Tokuda T et al (2007) Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 7(1):235\u2013242. https:\/\/doi.org\/10.1111\/j.1600-6143.2006.01585.x. PubMed PMID: 17061984","DOI":"10.1111\/j.1600-6143.2006.01585.x"},{"key":"10237_CR48","doi-asserted-by":"publisher","unstructured":"Judge DP, Heitner SB, Falk RH et al (2019) Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol 74(3):285\u2013295. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.012. PubMed PMID: 30885685","DOI":"10.1016\/j.jacc.2019.03.012"},{"key":"10237_CR49","doi-asserted-by":"crossref","unstructured":"Nelson LT, Paxman RJ, Xu J et al (2021) Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma. Amyloid 28(1):24\u201329 https:\/\/doi.org\/10.1080\/13506129.2020.1808783. PubMedPMID:32811187;PubMedCentralPMCID:PMCPMC7952025","DOI":"10.1080\/13506129.2020.1808783"},{"key":"10237_CR50","doi-asserted-by":"publisher","unstructured":"Toyama BH, Weissman JS (2011) Amyloid structure: conformational diversity and consequences. Annu Rev Biochem 80:557\u2013585. https:\/\/doi.org\/10.1146\/annurev-biochem-090908-120656. PubMed PMID:21456964;PubMed Central PMCID:PMCPMC3817101","DOI":"10.1146\/annurev-biochem-090908-120656"},{"key":"10237_CR51","doi-asserted-by":"publisher","unstructured":"Iadanza MG, Jackson MP, Hewitt EW et al (2018) A new era for understanding amyloid structures and disease. Nat Rev Mol Cell Biol 19(12):755\u2013773. https:\/\/doi.org\/10.1038\/s41580-018-0060-8. PubMed PMID: 30237470","DOI":"10.1038\/s41580-018-0060-8"},{"key":"10237_CR52","doi-asserted-by":"publisher","unstructured":"Ferrone F (1999) Analysis of protein aggregation kinetics. Methods Enzymol 309:256\u2013274. https:\/\/doi.org\/10.1016\/s0076-6879(99)09019-9 PubMed PMID: 10507029","DOI":"10.1016\/s0076-6879(99)09019-9"},{"key":"10237_CR53","doi-asserted-by":"publisher","unstructured":"Gallardo R, Ranson NA, Radford SE (2020) Amyloid structures: much more than just a cross-beta fold. Curr Opin Struct Biol 60:7\u201316. https:\/\/doi.org\/10.1016\/j.sbi.2019.09.001. PubMed PMID: 31683043","DOI":"10.1016\/j.sbi.2019.09.001"},{"key":"10237_CR54","doi-asserted-by":"publisher","unstructured":"Geddes AJ, Parker KD, Atkins ED et al (1968) \u201cCross-beta\u201d conformation in proteins. J Mol Biol 32(2):343\u2013358. https:\/\/doi.org\/10.1016\/0022-2836(68)90014-4. PubMed PMID: 5643439","DOI":"10.1016\/0022-2836(68)90014-4"},{"key":"10237_CR55","doi-asserted-by":"publisher","unstructured":"Bonar L, Cohen AS, Skinner MM (1969) Characterization of the amyloid fibril as a cross-beta protein. Proc Soc Exp Biol Med 131(4):1373\u20131375. https:\/\/doi.org\/10.3181\/00379727-131-34110. PubMed PMID: 5812002","DOI":"10.3181\/00379727-131-34110"},{"key":"10237_CR56","doi-asserted-by":"publisher","unstructured":"Sawaya MR, Sambashivan S, Nelson R et al (2007) Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 447(7143):453\u2013457. https:\/\/doi.org\/10.1038\/nature05695. PubMed PMID: 17468747","DOI":"10.1038\/nature05695"},{"key":"10237_CR57","doi-asserted-by":"publisher","unstructured":"Colletier JP, Laganowsky A, Landau M et al (2011) Molecular basis for amyloid-beta polymorphism. Proc Natl Acad Sci USA 108(41):16938\u201316943. https:\/\/doi.org\/10.1073\/pnas.1112600108. PubMed PMID:21949245; PubMed Central PMCID:PMCPMC3193189","DOI":"10.1073\/pnas.1112600108"},{"key":"10237_CR58","doi-asserted-by":"publisher","unstructured":"Glabe CG (2006) Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 27(4):570\u2013575. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2005.04.017 PubMed PMID: 16481071","DOI":"10.1016\/j.neurobiolaging.2005.04.017"},{"key":"10237_CR59","doi-asserted-by":"publisher","unstructured":"Johnson SM, Wiseman RL, Sekijima Y et al (2005) Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res 38(12):911\u2013921. https:\/\/doi.org\/10.1021\/ar020073i. PubMed PMID: 16359163","DOI":"10.1021\/ar020073i"},{"key":"10237_CR60","doi-asserted-by":"publisher","unstructured":"Schneider F, Hammarstrom P, Kelly JW (2001) Transthyretin slowly exchanges subunits under physiological conditions: a convenient chromatographic method to study subunit exchange in oligomeric proteins. Protein Sci 10(8):1606\u20131613. https:\/\/doi.org\/10.1110\/ps.8901. PubMed PMID:11468357; PubMed Central PMCID:PMCPMC2374086","DOI":"10.1110\/ps.8901"},{"key":"10237_CR61","doi-asserted-by":"publisher","unstructured":"Lai Z, Colon W, Kelly JW (1996) The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 35(20):6470\u20136482. https:\/\/doi.org\/10.1021\/bi952501g. PubMed PMID: 8639594","DOI":"10.1021\/bi952501g"},{"key":"10237_CR62","doi-asserted-by":"publisher","unstructured":"Colon W, Kelly JW (1992) Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31(36):8654\u20138660. https:\/\/doi.org\/10.1021\/bi00151a036. PubMed PMID: 1390650","DOI":"10.1021\/bi00151a036"},{"key":"10237_CR63","doi-asserted-by":"publisher","unstructured":"Yee AW, Aldeghi M, Blakeley MP et al (2019) A molecular mechanism for transthyretin amyloidogenesis. Nat Commun 10(1):925. https:\/\/doi.org\/10.1038\/s41467-019-08609-z. PubMed PMID:30804345; PubMed Central PMCID:PMCPMC6390107","DOI":"10.1038\/s41467-019-08609-z"},{"key":"10237_CR64","doi-asserted-by":"publisher","unstructured":"Saelices L, Johnson LM, Liang WY et al (2015) Uncovering the Mechanism of Aggregation of Human Transthyretin. J Biol Chem 290(48):28932\u201328943. https:\/\/doi.org\/10.1074\/jbc.M115.659912. PubMed PMID:26459562; PubMed Central PMCID:PMCPMC4661406","DOI":"10.1074\/jbc.M115.659912"},{"key":"10237_CR65","doi-asserted-by":"publisher","unstructured":"Dasari AKR, Hughes RM, Wi S et al (2019) Transthyretin aggregation pathway toward the formation of distinct cytotoxic oligomers. Sci Rep 9(1):33. https:\/\/doi.org\/10.1038\/s41598-018-37230-1. PubMed PMID:30631096; PubMed Central PMCID:PMCPMC6328637","DOI":"10.1038\/s41598-018-37230-1"},{"key":"10237_CR66","doi-asserted-by":"publisher","unstructured":"Marcoux J, Mangione PP, Porcari R et al (2015) A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. EMBO Mol Med 7(10):1337\u20131349. https:\/\/doi.org\/10.15252\/emmm.201505357. PubMed PMID:26286619; PubMed Central PMCID:PMCPMC4604687","DOI":"10.15252\/emmm.201505357"},{"key":"10237_CR67","doi-asserted-by":"publisher","unstructured":"Schmidt M, Wiese S, Adak V et al (2019) Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis. Nat Commun 10(1):5008. https:\/\/doi.org\/10.1038\/s41467-019-13038-z. PubMed PMID:31676763; PubMed Central PMCID:PMCPMC6825171","DOI":"10.1038\/s41467-019-13038-z"},{"key":"10237_CR68","doi-asserted-by":"publisher","unstructured":"Mangione PP, Porcari R, Gillmore JD et al (2014) Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. Proc Natl Acad Sci USA 111(4):1539\u20131544. https:\/\/doi.org\/10.1073\/pnas.1317488111. PubMed PMID: 24474780","DOI":"10.1073\/pnas.1317488111"},{"key":"10237_CR69","doi-asserted-by":"crossref","unstructured":"Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P (2008) Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol 216(2):253\u2013261","DOI":"10.1002\/path.2411"},{"key":"10237_CR70","doi-asserted-by":"crossref","unstructured":"Ihse E, Rapezzi C, Merlini G et al (2013) Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid 20:142\u2013150","DOI":"10.3109\/13506129.2013.797890"},{"key":"10237_CR71","doi-asserted-by":"publisher","unstructured":"Zhang J, Muthukumar M (2009) Simulations of nucleation and elongation of amyloid fibrils. J Chem Phys 130(3):035102. https:\/\/doi.org\/10.1063\/1.3050295. PubMed PMID:19173542; PubMed Central PMCID:PMCPMC2671213","DOI":"10.1063\/1.3050295"},{"key":"10237_CR72","doi-asserted-by":"publisher","unstructured":"Sousa MM, Fernandes R, Palha JA et al (2002) Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. Am J Pathol 161(5):1935\u20131948. https:\/\/doi.org\/10.1016\/S0002-9440(10)64469-0. PubMed PMID:12414539; PubMed Central PMCID:PMCPMC1850789","DOI":"10.1016\/S0002-9440(10)64469-0"},{"issue":"6","key":"10237_CR73","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/s0002-9440(10)63050-7.PubMedPMID:11733349;PubMedCentralPMCID:PMCPMC1850610","volume":"159","author":"MM Sousa","year":"2001","unstructured":"Sousa MM, Cardoso I, Fernandes R et al (2001) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 159(6):1993\u20132000. https:\/\/doi.org\/10.1016\/s0002-9440(10)63050-7. PubMedPMID:11733349 ; PubMed Central PMCID:PMCPMC1850610.","journal-title":"Am J Pathol"},{"key":"10237_CR74","doi-asserted-by":"publisher","unstructured":"Tipping KW, Karamanos TK, Jakhria T et al (2015) pH-induced molecular shedding drives the formation of amyloid fibril-derived oligomers. Proc Natl Acad Sci USA 112(18):5691\u20135696. https:\/\/doi.org\/10.1073\/pnas.1423174112.PubMed PMID:25902516 ; PubMed Central PMCID:PMCPMC4426459","DOI":"10.1073\/pnas.1423174112"},{"key":"10237_CR75","doi-asserted-by":"publisher","unstructured":"Serra-Vidal B, Pujadas L, Rossi D et al (2014) Hydrogen\/deuterium exchange-protected oligomers populated during Abeta fibril formation correlate with neuronal cell death. ACS Chem Biol 9(11):2678\u20132685. https:\/\/doi.org\/10.1021\/cb500621x. PubMed PMID: 25265274","DOI":"10.1021\/cb500621x"},{"key":"10237_CR76","doi-asserted-by":"publisher","unstructured":"Stewart KL, Hughes E, Yates EA et al (2016) Atomic Details of the Interactions of Glycosaminoglycans with Amyloid-beta Fibrils. J Am Chem Soc 138(27):8328\u20138331. https:\/\/doi.org\/10.1021\/jacs.6b02816 PubMed PMID: 27281497","DOI":"10.1021\/jacs.6b02816"},{"key":"10237_CR77","doi-asserted-by":"publisher","unstructured":"Stewart KL, Hughes E, Yates EA et al (2017) Molecular origins of the compatibility between glycosaminoglycans and Abeta40 amyloid fibrils. J Mol Biol 429(16):2449\u20132462. https:\/\/doi.org\/10.1016\/j.jmb.2017.07.003. PubMed PMID:28697887 ; PubMed Central PMCID:PMCPMC5548265","DOI":"10.1016\/j.jmb.2017.07.003"},{"key":"10237_CR78","doi-asserted-by":"publisher","unstructured":"Goodchild SC, Sheynis T, Thompson R et al (2014) beta2-Microglobulin amyloid fibril-induced membrane disruption is enhanced by endosomal lipids and acidic pH. PLoS One 9(8):e104492. https:\/\/doi.org\/10.1371\/journal.pone.0104492. PubMed PMID:25100247 ; PubMed Central PMCID:PMCPMC4123989","DOI":"10.1371\/journal.pone.0104492"},{"key":"10237_CR79","doi-asserted-by":"crossref","unstructured":"Viles J (2012) Metal ions and amyloid fiber formation in neurodegenerative diseases. Copper, zink and iron in Alzheimer's. Parkinson's and prion diseases. Coords Chem Rev 256:2271\u20132284","DOI":"10.1016\/j.ccr.2012.05.003"},{"key":"10237_CR80","doi-asserted-by":"publisher","unstructured":"Jucker M, Walker LC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501(7465):45\u201351. https:\/\/doi.org\/10.1038\/nature12481. PubMed PMID: 24005412","DOI":"10.1038\/nature12481"},{"key":"10237_CR81","doi-asserted-by":"publisher","unstructured":"Liberski PP (2014) Prion, prionoids and infectious amyloid. Parkinsonism Relat Disord Suppl 1:S80\u20134.\u00a0https:\/\/doi.org\/10.1016\/S1353-8020(13)70021-X. PubMed PMID: 24262195","DOI":"10.1016\/S1353-8020(13)70021-X"},{"key":"10237_CR82","unstructured":"Kisilevsky R, Axelrad M, Corbett W et al (1977) The role of inflammatory cells in the pathogenesis of amyloidosis. Lab Invest 37(6):544\u2013553. PubMed PMID: 599900"},{"key":"10237_CR83","doi-asserted-by":"crossref","unstructured":"Ranlov P (1967) The adoptive transfer of experimental mouse amyloidosis by intravenous injections of spleen cell extracts from casein-treated syngeneic donor mice. Acta Pathol Microbiol Scand 70(3):321\u2013335 PubMed PMID: 6083381","DOI":"10.1111\/j.1699-0463.1967.tb01300.x"},{"key":"10237_CR84","doi-asserted-by":"publisher","unstructured":"Paravastu AK, Qahwash I, Leapman RD et al (2009) Seeded growth of beta-amyloid fibrils from Alzheimer\u2019s brain-derived fibrils produces a distinct fibril structure. Proc Natl Acad Sci USA 106(18):7443\u20137448. https:\/\/doi.org\/10.1073\/pnas.0812033106. PubMed PMID:19376973 ; PubMed Central PMCID:PMCPMC2678625","DOI":"10.1073\/pnas.0812033106"},{"key":"10237_CR85","doi-asserted-by":"publisher","unstructured":"Prusiner SB (1998) Prions. Proc Natl Acad Sci USA 95(23):13363\u201313383. https:\/\/doi.org\/10.1073\/pnas.95.23.13363. PubMed PMID:9811807 ; PubMed Central PMCID:PMCPMC33918","DOI":"10.1073\/pnas.95.23.13363"},{"key":"10237_CR86","doi-asserted-by":"publisher","unstructured":"Collinge J (2001) Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 24:519\u2013550. https:\/\/doi.org\/10.1146\/annurev.neuro.24.1.519. PubMed PMID: 11283320","DOI":"10.1146\/annurev.neuro.24.1.519"},{"key":"10237_CR87","doi-asserted-by":"publisher","unstructured":"Aguzzi A, Calella AM (2009) Prions: protein aggregation and infectious diseases. Physiol Rev 89(4):1105\u20131152. https:\/\/doi.org\/10.1152\/physrev.00006.2009. PubMed PMID: 19789378","DOI":"10.1152\/physrev.00006.2009"},{"key":"10237_CR88","doi-asserted-by":"publisher","unstructured":"Caughey B, Baron GS, Chesebro B et al (2009) Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions. Annu Rev Biochem 78:177\u2013204. https:\/\/doi.org\/10.1146\/annurev.biochem.78.082907.145410. PubMed PMID:19231987 ; PubMed Central PMCID:PMCPMC2794486","DOI":"10.1146\/annurev.biochem.78.082907.145410"},{"key":"10237_CR89","doi-asserted-by":"publisher","unstructured":"Jarrett JT, Lansbury PT Jr (1993) Seeding \u201cone-dimensional crystallization\u201d of amyloid: a pathogenic mechanism in Alzheimer\u2019s disease and scrapie? Cell 73(6):1055\u20131058. https:\/\/doi.org\/10.1016\/0092-8674(93)90635-4. PubMed PMID: 8513491","DOI":"10.1016\/0092-8674(93)90635-4"},{"key":"10237_CR90","doi-asserted-by":"publisher","unstructured":"Werdelin O, Ranlov P (1966) Amyloidosis in mice produced by transplantation of spleen cells from casein-treated mice. Acta Pathol Microbiol Scand 68(1):1\u201318. https:\/\/doi.org\/10.1111\/apm.1966.68.1.1. PubMed PMID: 5954971","DOI":"10.1111\/apm.1966.68.1.1"},{"key":"10237_CR91","doi-asserted-by":"publisher","unstructured":"Goldsbury C, Baxa U, Simon MN et al (2011) Amyloid structure and assembly: insights from scanning transmission electron microscopy. J Struct Biol 173(1):1\u201313. https:\/\/doi.org\/10.1016\/j.jsb.2010.09.018. PubMed PMID:20868754 ; PubMed Central PMCID:PMCPMC3005892","DOI":"10.1016\/j.jsb.2010.09.018"},{"key":"10237_CR92","doi-asserted-by":"publisher","unstructured":"Knowles TP, Buehler MJ (2011) Nanomechanics of functional and pathological amyloid materials. Nat Nanotechnol 6(8):469\u2013479. https:\/\/doi.org\/10.1038\/nnano.2011.102. PubMed PMID: 21804553","DOI":"10.1038\/nnano.2011.102"},{"key":"10237_CR93","doi-asserted-by":"crossref","unstructured":"Dayeh MA, Livadiotis G, Elaydi S (2018) A discrete mathematical model for the aggregation of \u03b2-Amyloid. PLoS One 13(5):e0196402","DOI":"10.1371\/journal.pone.0196402"},{"key":"10237_CR94","doi-asserted-by":"publisher","unstructured":"Ripoll-Vera T, Alvarez J, Buades J et al (2019) Cardiac involvement after liver transplantation in patients with Val30Met transthyretin amyloidosis from Majorca focus. Amyloid 26(sup1):18\u201319. https:\/\/doi.org\/10.1080\/13506129.2019.1582487. PubMed PMID: 31343328","DOI":"10.1080\/13506129.2019.1582487"},{"key":"10237_CR95","doi-asserted-by":"publisher","unstructured":"Banerjee D, Roeker LE, Grogan M et al (2017) Outcomes of Patients With Familial Transthyretin Amyloidosis After Liver Transplantation. Prog Transplant 27(3):246\u2013250. https:\/\/doi.org\/10.1177\/1526924817715463. PubMed PMID: 29187090","DOI":"10.1177\/1526924817715463"},{"key":"10237_CR96","doi-asserted-by":"publisher","unstructured":"Yoshinaga T, Yazaki M, Sekijima Y et al (2016) The pathological and biochemical identification of possible seed-lesions of transmitted transthyretin amyloidosis after domino liver transplantation. J Pathol Clin Res 2(2):72\u201379. https:\/\/doi.org\/10.1002\/cjp2.36. PubMed PMID:27499917 ; PubMed Central PMCID:PMCPMC4907057","DOI":"10.1002\/cjp2.36"},{"key":"10237_CR97","doi-asserted-by":"publisher","unstructured":"Buxbaum JN, Tagoe C, Gallo G et al (2012) Why are some amyloidoses systemic? Does hepatic \u201cchaperoning at a distance\u201d prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis? FASEB J 26(6):2283\u20132293. https:\/\/doi.org\/10.1096\/fj.11-189571. PubMedPMID:22362898 ; PubMed Central PMCID:PMCPMC3360152","DOI":"10.1096\/fj.11-189571"},{"key":"10237_CR98","doi-asserted-by":"publisher","unstructured":"Koloteva-Levine N, Aubrey LD, Marchante R et al (2021) Amyloid particles facilitate surface-catalyzed cross-seeding by acting as promiscuous nanoparticles. Proc Natl Acad Sci USA 118(36). https:\/\/doi.org\/10.1073\/pnas.2104148118. PubMed PMID: 34462352; PubMed Central PMCID: PMCPMC8433567","DOI":"10.1073\/pnas.2104148118"},{"key":"10237_CR99","doi-asserted-by":"publisher","unstructured":"Ivanova MI, Lin Y, Lee YH et al (2021) Biophysical processes underlying cross-seeding in amyloid aggregation and implications in amyloid pathology. Biophys Chem 269:106507. https:\/\/doi.org\/10.1016\/j.bpc.2020.106507. PubMed PMID: 33254009","DOI":"10.1016\/j.bpc.2020.106507"},{"key":"10237_CR100","doi-asserted-by":"publisher","unstructured":"Schwarzman AL, Tsiper M, Wente H et al (2004) Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants. Amyloid 11(1):1\u20139. https:\/\/doi.org\/10.1080\/13506120410001667458. PubMed PMID: 15185492","DOI":"10.1080\/13506120410001667458"},{"key":"10237_CR101","doi-asserted-by":"publisher","unstructured":"Buxbaum JN, Ye Z, Reixach N et al (2008) Transthyretin protects Alzheimer\u2019s mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci USA 105(7):2681\u20132686. https:\/\/doi.org\/10.1073\/pnas.0712197105. PubMed PMID:18272491 ; PubMed Central PMCID: PMCPMC2268196","DOI":"10.1073\/pnas.0712197105"},{"key":"10237_CR102","doi-asserted-by":"publisher","unstructured":"Choi SH, Leight SN, Lee VM et al (2007) Accelerated Abeta deposition in APPswe\/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin). J Neurosci 27(26):7006\u20137010. https:\/\/doi.org\/10.1523\/JNEUROSCI.1919-07.2007. PubMed PMID:17596449 ; PubMed Central PMCID:PMCPMC6672232","DOI":"10.1523\/JNEUROSCI.1919-07.2007"},{"key":"10237_CR103","doi-asserted-by":"publisher","unstructured":"Pomfret EA, Lewis WD, Jenkins RL et al (1998) Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy. Transplantation 65(7):918\u2013925. https:\/\/doi.org\/10.1097\/00007890-199804150-00010. PubMed PMID: 9565095","DOI":"10.1097\/00007890-199804150-00010"},{"key":"10237_CR104","doi-asserted-by":"publisher","unstructured":"Jiang X, Smith CS, Petrassi HM et al (2001) An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry 40(38):11442\u201311452. https:\/\/doi.org\/10.1021\/bi011194d. PubMed PMID: 11560492","DOI":"10.1021\/bi011194d"},{"key":"10237_CR105","doi-asserted-by":"publisher","unstructured":"Tagoe CE, French D, Gallo G et al (2004) Amyloidogenesis is neither accelerated nor enhanced by injections of preformed fibrils in mice transgenic for wild-type human transthyretin: the question of infectivity. Amyloid 11(1):21\u201326. https:\/\/doi.org\/10.1080\/13506120410001674982. PubMed PMID: 15185495","DOI":"10.1080\/13506120410001674982"},{"key":"10237_CR106","doi-asserted-by":"publisher","unstructured":"Wei L, Kawano H, Fu X et al (2004) Deposition of transthyretin amyloid is not accelerated by the same amyloid in vivo. Amyloid 11(2):113\u2013120. https:\/\/doi.org\/10.1080\/13506120410001726344. PubMed PMID: 15478467","DOI":"10.1080\/13506120410001726344"},{"key":"10237_CR107","doi-asserted-by":"publisher","unstructured":"Sevigny J, Chiao P, Bussiere T et al (2016) The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature 537(7618):50\u201356. https:\/\/doi.org\/10.1038\/nature19323. PubMed PMID: 27582220","DOI":"10.1038\/nature19323"},{"key":"10237_CR108","doi-asserted-by":"publisher","unstructured":"Saelices L, Pokrzywa M, Pawelek K et al (2018) Assessment of the effects of transthyretin peptide inhibitors in Drosophila models of neuropathic ATTR. Neurobiol Dis 120:118\u2013125. https:\/\/doi.org\/10.1016\/j.nbd.2018.09.007. PubMed PMID:30213731 ; PubMed Central PMCID:PMCPMC6186191","DOI":"10.1016\/j.nbd.2018.09.007"},{"key":"10237_CR109","doi-asserted-by":"publisher","unstructured":"Su Y, Jono H, Torikai M et al (2012) Antibody therapy for familial amyloidotic polyneuropathy. Amyloid 19(Suppl 1):45\u201346. https:\/\/doi.org\/10.3109\/13506129.2012.674075. PubMed PMID: 22506915","DOI":"10.3109\/13506129.2012.674075"},{"key":"10237_CR110","doi-asserted-by":"publisher","unstructured":"McGregor DP (2008) Discovering and improving novel peptide therapeutics. Curr Opin Pharmacol 8(5):616\u2013619. https:\/\/doi.org\/10.1016\/j.coph.2008.06.002. PubMed PMID: 18602024","DOI":"10.1016\/j.coph.2008.06.002"},{"key":"10237_CR111","doi-asserted-by":"crossref","unstructured":"Langer R, Brown L, Edelman E (1985) Controlled release and magnetically modulated release systems for macromolecules. Methods Enzymol 112:399\u2013422. https:\/\/doi.org\/10.1016\/s0076-6879(85)12032-x.\u00a0PubMed PMID: 4046857","DOI":"10.1016\/S0076-6879(85)12032-X"},{"key":"10237_CR112","doi-asserted-by":"publisher","unstructured":"Van Regenmortel MH (2001) Antigenicity and immunogenicity of synthetic peptides. Biologicals 29(3\u20134):209\u201313. https:\/\/doi.org\/10.1006\/biol.2001.0308. PubMed PMID: 11851317","DOI":"10.1006\/biol.2001.0308"},{"key":"10237_CR113","doi-asserted-by":"publisher","unstructured":"Werle M, Bernkop-Schnurch A (2006) Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30(4):351\u2013367. https:\/\/doi.org\/10.1007\/s00726-005-0289-3. PubMed PMID: 16622600","DOI":"10.1007\/s00726-005-0289-3"},{"key":"10237_CR114","doi-asserted-by":"crossref","unstructured":"Haggag YA, Donia AA, Osman MA, El-Gizawy SA (2018) Peptides as drug candidates: limitations and recent development perspectives. Biomed J Sci 8:6659\u20136662","DOI":"10.26717\/BJSTR.2018.08.001694"},{"key":"10237_CR115","doi-asserted-by":"publisher","unstructured":"Si JB, Kim B, Kim JH (2021) Transthyretin misfolding, a fatal structural pathogenesis mechanism. Int J Mol Sci 22(9):4429. https:\/\/doi.org\/10.3390\/ijms22094429","DOI":"10.3390\/ijms22094429"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-022-10237-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-022-10237-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-022-10237-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T03:17:05Z","timestamp":1665112625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-022-10237-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":115,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10237"],"URL":"https:\/\/doi.org\/10.1007\/s10741-022-10237-7","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,6]]},"assertion":[{"value":"26 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this paper was updated to add funding note.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}